VOWST is the FIRST and ONLY orally
administered microbiome therapeutic to
prevent Clostridioides difficile (C. diff) recurrence1,2
SUPERIOR PREVENTION OF
C. DIFF
RECURRENCE
COMPARED TO ANTIBIOTICS ALONE
Statistically significant reduction of C. diff recurrence ( P <0.001)1-3
PROVEN EFFICACY
AT 8 WEEKS1,2
ECOSPOR III
PRIMARY ENDPOINT
DURABLE RESPONSE
AT 24 WEEKS1,3
ECOSPOR III
SECONDARY ENDPOINT
† Calculated by the rate of C. diff recurrence, which was significantly lower in VOWST recipients compared to those receiving antibiotics alone—12% vs. 40%, respectively—a 0.32 relative risk (95% confidence interval, 0.18, 0.58; P <0.001).1,2
‡ Relative risk of 0.46 (95% CI, 0.30, 0.73).
ECOSPOR III was a Phase 3, multicenter, double-blind, randomized, placebo-controlled trial evaluating C. diff recurrence at 8 weeks; secondary endpoints at 4, 12, 24 weeks. In the intent-to-treat population, participants received standard-of-care antibiotics (vancomycin/fidaxomicin) and laxative followed by VOWST or placebo. Those lost to follow-up, terminated prematurely, or died prior to end of study time interval counted as a recurrence. Data were rounded to the nearest whole number for presentation.
VOWST WAS GENERALLY WELL TOLERATED THROUGH 8 WEEKS1
The majority of adverse reactions were mild or moderate in severity1
The most common adverse reactions (reported in ≥5% of VOWST-treated participants and at a rate greater than placebo) were abdominal distension (31%), fatigue (22%), constipation (14%), chills (11%), and diarrhea (10%)1
No serious adverse events were considered related to the use of VOWST1
Consider prescribing VOWST and antibiotics at the
same time to help ensure patients get access to
VOWST at the time of completing antibiotics
REFERENCES: 1.
VOWST [Prescribing Information]. Cambridge, MA: Seres Therapeutics, Inc. and Nestlé Health Science. 04/2023.
